[
    {
        "text": "hey everyone welcome to the drive podcast I'm your host Peter attia all right kellyanne great to be sitting down with you and talking about all things neurodegenerative disease this is something I've been looking forward to for a while and um I don't know I thought maybe just to begin kind of give us a bit of a sense of your background and how this has become of interest to you did you always know you want to become a doctor so thanks for having me I'm super excited to be on the show finally um so it's an interesting question I'm gonna say I always wanted to be a doctor sparing the fact that when I was younger I thought maybe I would be a singer or a mermaid or something crazy like that I loved scuba diving so I had a large fantasy but that's a good point mermaid can combine the love for scuba diving with singing It's like it really is the perfect career it was the perfect career for me but uh no I was always a nerd actually I don't know if I'm allowed to say this but in high school the quarterback of the football team joked and said that I was a waste of pretty because I never went to any parties and all I did was study I was obsessed with Biology and obsessed with chemistry and was a bookworm pretty much and did the brain always interest you did you always have a sense I mean so it's I found that interesting you know a subset of people when they go to medical school already know what they're going to do many people do not were you that person who when interviewing for medical school knew you wanted to do neurology no not at all actually so I'm a first generation American my dad and mom Bolton give me a lot of coaching when I was growing up but one thing that they taught me was whatever you're gonna do just love it because you're going to do it for the rest of your life and when I was in medical school I just loved learning so I loved every single subject",
        "start": "00:00:01",
        "duration": 214.21900000000002,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "but when I got into the clinical rotations I found myself a little disappointed in them because I wasn't interested in the algorithms of the disease and the actual treatments that were being offered and when I was thinking about things like prevention or exercise or Diet I pretty much just got shunned so when I was thinking about Specialties I thought about what could I read for the rest of my life and be fascinated by and that was pretty much the brain for me now a lot of people will say neurology is a a pretty depressing specialty because um a lot of the patients you're caring for have conditions that can't really be reversed so um at least in my med school neurology was not a core rotation we were not required to do it so I assume that was the same for you and you did it as an elective yes I did it as an elective and it is so depressing most of these diseases almost all of them we don't have effective treatments for sparing things like migraines and Ms now but glioblastoma terrible disease terrible treatment options not much has changed in the field and when you think about things like neurodegenerative disease which is ultimately what I went into the diseases are devastating for both the patients and their families now you did your neurology residency at Cornell which is how you met our mutual friend Richard isakson and that's of course how we became connected um and then you did a fellowship at Mount Sinai in movement disorders specifically yes I want to take a step back and make sure people including myself understand the breadth of this field called neurodegeneration so when you look at the Actuarial statistics of mortality neurodegeneration accounts for the third leading cause of death so you have all of the diseases that are lumped under",
        "start": "00:01:50",
        "duration": 249.56200000000004,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "ascvd atherosclerotic cardiovascular and cerebrovascular disease that's number one cancer is number two and then neurodegenerative disease is number three and those three basically account for sorry there's one other which actually no no those do those are the top three and I think they account for 70 of death um quite a sobering thought now within neurodegenerative disease you you have a lot of different types of pathology some of which we've spent a lot of time on this podcast talking about we've talked a lot about Alzheimer's disease we're going to talk about that again today but what I want to do today is be more broad because in getting to know you I've come to understand that there are some of these diseases that affect men more than women and we have a far better sense of how to discriminate between these diseases than I used to think we did I used to think that you know for example Alzheimer's disease and Lewy Body dementia could only be distinguished on an autopsy that they couldn't be distinguished clinically I used to never think about Parkinson's disease in the same way that I would think about say a cognitive disease and I really until recently never understood the differences in the patterns of where the disease occurred in the brain and how that translated to deficits now the other day you explained it to me in a way that I thought was so elegant looking at the different parts of the brain maybe you could sort of rehash some of that for folks yeah so let's take a step back and talk about dementia which is an umbrella term and then a further step back which is neurodegeneration which encompasses dementias and other processes like Parkinson's disease so when we think about neurodegeneration everyone thinks about",
        "start": "00:03:55",
        "duration": 207.939,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "Alzheimer's disease because it's the most prevalent and chances are you know somebody who was affected by this disease but the other diseases that we're going to talk about today are also very common and you've probably never heard of them but you you should because there's a reasonable likelihood that they will affect you at some point in your life or a loved one so when we think about dementia what falls under that umbrella we have Alzheimer's disease we have vascular dementia we have Lewy Body dementia frontal temporal dementia but when we think about neurodegeneration as a more Broad term we start thinking about diseases like Parkinson's disease Huntington's disease ALS and then more rare diseases like Progressive super nuclear palsy multiple system atrophy cortical basil or degeneration so taking a step back in terms of understanding what these diseases are and what symptoms people may present at I like to look at it as what part of the brain is this affecting so neurodegeneration means death of the brain cells where is that death happening so for things like frontotemporal Dementia or vascular dementia you're talking about the frontal lobe primarily and the frontal lobe is involved in processes such as planning events problem solving speed of processing these are all executive lobe functions when we think about um Alzheimer's disease we're thinking about the temporal lobe that's where the degeneration is mainly happening and that's mainly a memory problem but it's also a language problem The Language Center is in the temporal lobe for diseases like Lewy Body we're thinking about the parietal and occipital lobe the parietal occipital lobe are involved with visual spatial processing so you get symptoms like issues with depth",
        "start": "00:05:39",
        "duration": 236.45999999999998,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "perception issues following plot lines of movies or following plot lines of books patients will have to reread passages over again to really fully comprehend what's happening and hallucinations is something that you can see later in the disease course and is the difficulty with depth perception part of what feeds into the movement disorder of that we see that kind of differentiates Lewy Body from A.D yeah I really think so and it's interesting and we'll talk about this later so maybe a little sticky note it for now but visual impairment is a risk factor for neurodegenerative diseases and how does that relate to how we can prevent these diseases well it's possible that the visual processing is needed to reinforce the neuronal circuitry and what I mean by that is our brain needs sensory input it needs sensory stimulation when we don't have that those neuronal circuits aren't getting exercised for lack of a better term and they're more likely to atrophy so if you don't use it you lose it and so in relation to your question yes I think that that visual processing is why you have the depth perception issues that you see in Lewy Body so I definitely will make a note of that because I want to come back to not just the visual part but the auditory part as well yes I want to go back to something you you mentioned the outset um you talked about how vascular dementia overlaps with frontal dementia what is it about that when I think of vascular dementia in my mind I'm thinking of small vessel disease that's similar to atherosclerotic disease basically some form of ischemia um why is that unique to the frontal cortex and why is that not something that you know the rest of the brain is just as sensitive to so I actually think vascular dementia and Alzheimer's dementia are the ones that overlap more and the reason I say",
        "start": "00:07:37",
        "duration": 244.67999999999998,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "that is because it's very difficult to discern clinically the difference between Alzheimer's and vascular dementia we classically will say yes the speed of processing issues or more prevalent in vascular dementia versus Alzheimer's disease it's more of a memory issue but um when we're looking at metabolic changes in the brain we see that the frontal lobe is hypometabolic in terms of glucose utilization in frontotemporal dementia and in vascular dementia and why is that it's hard to know exactly but it may have something to do with the vasculature of the brain and what areas of the brain are more sensitive to glucose metabolism cholesterol metabolism and Vascular risk factors yeah it's very interesting because there is such a high association with diabetes in the in this condition but my recollection is that the brain doesn't require insulin the way the rest of the body does to facilitate glucose transport into neurons in other words insulin resistance per se should not be an issue in the brain proper but of course I've seen experimental data that look at intranasal insulin injections that temporarily alleviate some of the symptoms associated with this type of dementia suggesting that maybe insulin resistance is playing a role paradoxically and of course you always have to wonder if the metabolic syndrome that is associated with type 2 diabetes in that entire spectrum is simply a marker of the underlying vascular problems as well so this is an area kellyanne where I really find myself confused in the end it might not matter that much from a preventative strategy but nevertheless it creates a little bit of confusion in terms of mechanism of action at least in my naive mind it's really interesting clinically when you",
        "start": "00:09:39",
        "duration": 226.26000000000002,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "look at data so we do cognitive testing on a ton of patients so we get to look at this in real time and we get to compare it to serum biomarkers so thinking about high cholesterol meaning High apob when we see high apob in patients we often do see reduced speed of processing and clinically we see that if you correct things like the apob you see Improvement in speed of processing and tell me again tell me about the time course there yeah it can happen rather quickly over a course of six months but it's dependent on the purpose on the person that's that's kind of amazing I mean obviously we take this approach with patients but a lot of our patients that are in our practice don't really have the MCI that you are seeing in your clinic um you know the patients that you and Richard took care of at Cornell were obviously far more advanced and um is there a point at which you just didn't see any Improvement in symptoms regardless of intervention so like I said everyone's different and there are a lot of different factors that could influence something like executive function and speed of processing I think what's most helpful is looking at a individual and putting their lab values and an understanding of what their risk factors are next to each other because if you see somebody who for example does have out of control cholesterol and you're looking at their executive function in tasks like generating words that start with f or a or S that's a really popular test that gives us Clues into is the vascular risk factor affecting this person's cognition if you see that the chance that you intervene on their cholesterol and they have a notable outcome in the next 6 12 18 months is pretty high but it depends on the person and it also depends on",
        "start": "00:11:33",
        "duration": 223.26000000000005,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "what other factors are playing a role for example sleep sleep is huge and I can't emphasize enough how important sleep is to speed of processing if you are getting crap sleep sorry you really aren't going to see high speed of processing you really have to be sleeping in order to process information so I want to put a pin in that as well because I do want to come back to sleep staging we've obviously separately and previously talked a lot about REM sleep disruption and the implications for that so I want to come back to sleep but let's go back to kind of this broader sense of what's going on so you have sort of these three areas of the brain that can be impacted that can lead to various types of dementia and each of them seems horrible in their own right uh ironically Alzheimer's seems the least horrible in that it's mostly a deficit of memory and language relative to robbing you of executive function processing speed in the front of the brain and movement disorders and visual disorders in the in the back of the brain but to be sure these are all awful conditions let's talk a little bit about some of the the the um the things that we think about more with refractive movement so Parkinson's disease and obviously the perhaps the worst disease of them all ALS so ALS and Parkinson's disease are very different because ALS is more of a peripheral nerve problem Parkinson's disease is more of a central problem more related to Lewy Body ALS is really rare only about 18 000 people in the US have ALS um unlike Parkinson's disease which is much more common a million people in the US have Parkinson's disease and the incidence of Parkinson's disease is actually doubled in the last 25 years it's the fastest growing neurological",
        "start": "00:13:25",
        "duration": 240.83900000000003,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "condition in and just for comparison how many people in the United States carry a diagnosis of Alzheimer's disease about 6 million okay so 6 million to one million yep two you know eighteen thousand yep and for Lewy Body it's about 1.4 million so less common than Alzheimer's disease but still that's actually pretty common that's 25 of it right but still very common so still reasonable likelihood that someone listening to this podcast today is going to be affected by one of these diseases ALS less so but the interesting thing about ALS is that there's a connection between ALS and frontal temporal dementia so there are certain genetic risk factors one is C9 ORF that's what I say c9orf it puts people at risk for both ALS and frontotemporal dementia so some family members will have the frontotemporal dementia and other family members will have ALS we don't know what turns one person to develop the more peripheral nerve problem versus the more Central nerve problem but it's an interesting connection that you'll you'll see now Parkinson's again it's I didn't realize it was quite that prevalent so is it a different disease when it occurs in young people than when it occurs in older people or is it basically the same disease and it just has a variable time of onset so we in my opinion aren't very good at the way we're diagnosing these diseases so we're using a clinical diagnosis to say somebody has Parkinson's disease so you need to have resting Tremor bradykinesia which is slow movements rigidity which is stiffness of the muscles and or postural instability so falling not being steady on your feet that is a really rudimentary way of looking at the disease yes it's saying that there's something going on in the brain that you're losing dopamine neurons but really these diseases are starting way way way before those symptoms are actually presenting so if",
        "start": "00:15:24",
        "duration": 244.44199999999998,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "you look at people who have REM sleep behavior disorder which is acting out your dreams so punching kicking screaming in your sleep that is over 90 percent positive predictive value that you will go on to develop either a Parkinson's or Lewy Body like disease and that starts 20 to 30 years before a Tremor or muscle stiffness or postural instability will ever present wait that that's that's going to be a little scary to some people because I think a lot of us think well I move around a lot in my sleep but how is this diagnosis made is it is it relying on a spouse or someone in the bed with you or is it something that can only be done with polysomnography so the gold standard is polysamography but you actually don't need polysomnography to diagnose it and in fact one simple question has a greater than 90 percent sensitivity and specificity for picking up REM sleep behavior disorder which is does your bed partner know that you are punching kicking or moving a lot in your sleep and when we're saying moving a lot we're not just talking about tossing and turning or talking about it's clear that this person is having some sort of dream and they are acting that out in their sleep it's different than just the and to be clear are you saying that if that exists so if someone in their 30s is experiencing that there's roughly a 90 chance they're going to go on to develop Parkinson's disease or Lewy Body dementia correct and it's a terrifying fact it is a terrifying fact but this the way that I think about it is knowing that is like picking up breast cancer when it's localized to the breast tissue the way that we're doing it now we're picking up Parkinson's Disease by the time we get the diagnosis of Parkinson's disease so by the time someone has Tremor rigidity yeah it's like diagnosing metastatic breast cancer yes 50 of the dopamine producing brain",
        "start": "00:17:27",
        "duration": 253.01999999999995,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "cells are already gone okay so let's let's actually tell people a little bit about what's going on in Parkinson's disease so let's explain what dopamine is in the basal ganglia and all these things so that people understand how that happens and so let's let's spend three minutes on just the med school explanation uh because I think it's important to understand you have to understand a little bit about the anatomy and the neurobiology of this to understand the prevention stuff that we're going to want to talk about so so what's happening in also in uh in Parkinson's disease so rudimentary Medical School 101 what is happening in Parkinson's disease so dopamine producing brain cells so dopaminergic cells live in a part of the brain called the substantia pars compacta which is a center that controls movement in the body these cells are dark colored and in Parkinson's disease these cells start to to die you need dopamine so these cells produce dopamine you need dopamine to move but you also need dopamine for a slew of other neurological processes including mood regulation so if you don't have adequate dopamine you often suffer from anxiety and depression so do we have any sense of what leads to the loss of those cells so what are the risk factors for Parkinson's Disease is what you're asking yeah or even just more pathologically like for example has it been ruled out that it's autoimmune is there any reason to believe that the immune system is attacking those cells and destroying them um is it you know does it seem to be unaffected by anything else is it program cell death presumably not is it inflammatory is it is it an inflammatory environment that destroys those dopamine producing cells do we have some sense of",
        "start": "00:19:34",
        "duration": 220.14000000000007,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "what it is mechanistically that's doing this so the immune system and inflammation seem to play a large role here but it may be more related to the mitochondria and the lysosome function so autophagy and removing damaged organelle seems to play a really big role in these diseases um which seems to be a Common Thread across all of neurodegeneration we've talked about this on a previous podcast with Eileen white guy that's probably been two and a half years ago but uh one of the surest ways to impart neurodegenerative disease onto a mouse is to knock out the genes responsible for autophagy they'll basically all succumb to neurodegeneration I I want to say it's something as absurd as at four months of age now four months for a mouse right that's the equivalent of oh I don't know probably 15 or 20 years old for a human maybe less um and to think that if the only thing you've done is knock out autophagy you might argue well they would have gotten other diseases later on but that the very first thing that they get and the thing that ultimately kills them is neurodegeneration probably speaks to the importance of this process in homeostasis within the brain absolutely and I mean we don't have perfect models for Parkinson's Disease because the models that we use are either models that are induced by toxic exposures or genetic models which there's no one size fits all I think this disease is just so Broad and can present in many different ways and can have many different etiologies but if you look at the genetic models for the disease really one of the main genes called GBA and what happens is that a enzyme gets stuck the uh the glucose cerebrosidase enzyme gets stuck in the endoplasmic reticulum and it can't break down glucose fingosines so you're not getting these chemicals broken down where they",
        "start": "00:21:24",
        "duration": 242.27899999999994,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "should be they start building up and when they start building up the lysosome can't get to these substances to break them down appropriately so the lysosomal function is really impaired and once you start impairing the lysosomal function then the mitochondria becomes affected then you start triggering a whole slew of inflammatory cytokines and the process just is a vicious cycle two questions then you can take them in whichever order you like do we have a sense of what are the causative triggers not just associative what are the causative triggers of Parkinson's disease we should talk about the same for Lewy Body Of course as well but let's just focus on one and secondly if you're talking to that person who's 40 years old who is having the Sleep disturbances that we now think have a high likelihood of predicting the beginning of this damage what do you do so this is touching on so many points so if you want to first start with what is triggering the disease well we don't have the perfect answer but we know certain things do trigger it or seem to play a role so pesticide exposure seems to play a role solventix which are pesticides do we know yeah so it's paraquat and rhodonone um which road known is not used in the U.S anymore but paraquat is still used in the U.S so we see a higher prevalence of Parkinson's disease in people who live in more rural places in the U.S and if you look at epidemiological studies on where is Parkinson's Disease distributed in the U.S you'll see there is a quote Parkinson's disease belt and it really runs through the Midwest of course the USDA and the FDA would never acknowledge this because they would they would have to say that this is just noise and that there's no data there or they would have banned",
        "start": "00:23:25",
        "duration": 245.76099999999994,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "this pesticide so what is it that you think that they don't see in those data or or How would how are they explaining that away as a confounder for something else you know I don't think I have a very good answer to that I don't know why they don't acknowledge that these studies are real and these associations are pretty profound there's clearly just like there's a stroke belt in the South there's a stroke there's a Parkinson's disease disease belt in the midwest do we what are these what are these pesticides used for agricultural farming Foods in particular is it I don't know okay and you probably don't know if there's substitutes that could be used at a slightly higher costs that are less toxic I'm not sure um are these pesticides in Greater use today what explains the fact that you said earlier Parkinson's is the fastest growing neurodegenerative condition in the U.S yeah great question and there have been a lot of theories hypothesizing why the prevalence of Parkinson's disease will grow in the future and one of them which makes me laugh a little bit is smoking so smoking is quote protective against Parkinson's disease it's like one of those weird things that you read about and you're like oh wait why just like I think inflammatory bowel disease also smoking is quote protective against it and they're saying well less people are smoking now so maybe that's what's driving the disease but I don't really buy into that because I don't really think smoking's offering that much protection to your brain and it's doing so many other terrible things for your brain and body that it's just not something to ever consider when we're thinking about ways to optimize our health um I actually think it has a lot to do with the movements that were going",
        "start": "00:25:28",
        "duration": 238.73999999999992,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "through day to day and how much screen time we're spending every day but we can touch more on that later so you think it's um a loss of movement capacity basically exactly and just like we were talking about or I think Richard talked about it in his podcast the idea of cognitive Reserve building as much cognitive Reserve as possible well you want the same with your body you want to build up as much movement Reserve as possible because if you don't use it you lose it and the less you move the more likely you are to develop one of these neurodegenerative movement processes I believe how many of those cases of Parkinson's disease percent wise do we think uh have a clear genetic predisposition and you mentioned one gene already uh you know we we were going to talk a lot about the genes around Alzheimer's disease uh what is the genetic landscape look like here so right now we say 10 of Parkinson's disease is related to a clear genetic etiology GBA is one gene lark2 lrrk2 is another one and both of these genes are tested in 23andMe only one variant of each so it's not a perfect test so if it's negative for you it doesn't really mean you don't have a variant in one of these genes but those are the most common there are other lessons are these more like apoe for where they are risk factors but they're not fully penetrant in the way that Huntington's is yes okay exactly so if you have one of these genes it depends on a lot of factors especially ancestry so Ash Jewish people with Ashkenazi Jewish ancestry have a higher risk that these genes will Express but we're looking at penetrance of around 30 percent but for Lark 2 it can be much higher up to 80 percent some studies quote actually 100 depending on how long you live but I don't know if I believe it okay but not a huge",
        "start": "00:27:27",
        "duration": 255.72000000000003,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "he said that's ten percent ten percent yeah whereas in Alzheimer's disease two-thirds of cases have E4 at least one copy of E4 so you could say E4 is playing a bigger role there potentially yeah I would say that our understanding of Parkinson's disease is so far behind our understanding of Alzheimer's disease and our understanding of the genetic architecture of it is so far behind I would say that we're probably at least 10 years behind the field of Alzheimer's disease and we will identify more genetic risk factors for this disease I have no doubt about it because the number of patients that I've seen that have a clear family history and multiple family members and testing for every known Gene that we could has just turned up nothing there's clearly something there that we are missing yeah so so again we see this also with breast cancer we see women in whom breast cancer runs in the family up and down sideways and they test negative for every known Gene associated but you've got to tell that woman your daughter's at risk even though we can't identify what the genes are yeah which makes it really challenging as a provider because we love looking at genes because it gives us a clue to what the possible underlying pathophysiological mechanism that may be driving the disease that they may be at risk for when we don't have that to grab onto we're really grabbing at straws and just throwing everything under under the kitchen sink at a person because we don't really have a good clear sense of what pathway they're on so um what would what do you say to that person who's 40 who's having these sleep disturbances uh but during you know while they're awake everything is totally fine so the idea here being that those sleep disturbances are the Canary and the coal mine for this problem occurring in their",
        "start": "00:29:35",
        "duration": 229.25900000000004,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "brain um what's what what do you say to that patient as far as steps to take to maximize the odds of avoidance or at least maximum maximal delaying so again not there's no one size fits all here so it really depends on the person and the first thing I'd want to do is definitely check out their genes but besides that so let's say you do this and they don't uh they don't test positive for the for either of these two genes um and yeah let's just let's say you have access to everything what do you want to know what else do you know about this person what toxic exposures could they have or did they grow up were they drinking well water were they drinking City water all those things matter so let's say they grew up on a farm but now they don't live anywhere near it so their their exposure is in the past it's no longer present um and let's assume that that there's nothing that's actively contributing to it from a from an exposure standpoint and now you're just kind of going on defense as far as what you can do okay so first and foremost a movement assessment is absolutely key so the one thing that I think is so fascinating about this disease is that we see abnormal movement patterns in these patients years and years before Tremor slow movement start and the patterns that we see are very similar among people so most frequently and maybe we should rewind a little bit here so her bodies are naturally asymmetric just like our brains are naturally asymmetric we have despite the way they look our bodies look symmetric our brains looks metric but we know that the right side of the brain has certain functions and the left side of the brain has certain functions so the left side is really a language",
        "start": "00:31:30",
        "duration": 228.90000000000003,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "verbal side and the right side is more of a visual side emotional side we have a dominance for one hand and one leg so in people who are right-handed which is most people will see the symptoms start of Parkinson's Disease start in the dominant hand and be most severe in the dominant hand so taking into account someone's handedness the pattern of movement that we usually see is patients don't really load the left leg and they won't spend time on the left leg so most of their time is bent on the right leg and they can't really sense or get a good sense of grounding through the left leg and the right arm is stiff and not swinging very freely when they're walking that is something if you see REM sleep behavior and this abnormal movement pattern I want to deconstruct their movement and make them Sense on the left side and free up the right side which often starts with breathing because they're also not really breathing into the right apical lung or the right lung at all so first deconstructing that into what is their abnormal breathing pattern and how can we get them to feel on the left side and move the right side more freely so obviously this overlaps a lot with with stuff that Beth Lewis and I talk about and and you and Beth of course are very close and work together with patients as well um is the idea here that you can start to train out the pathology if that makes sense yeah I I think I like the way you put that train out the pathology I think that you know everyone has asymmetries in their body the problem is when that asymmetry goes too far in one extreme and that can happen for a lot of different reasons it may be triggered by an orthopedic injury for me for example I actually noticed this so I had a spinal fusion when I was just a teenager and I thought I was totally fine until my med school",
        "start": "00:33:24",
        "duration": 265.86000000000007,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "boyfriend took me skiing and I realized I could not control my right leg no matter what I did I couldn't get my brain to talk to my right leg to make my right leg and internally rotate and that showed me that there is some poor control between my leg and my brain that neuronal circuitry is just not developed appropriately and that's what you're trying to reinforce because by building up stronger circuitry between all aspects of your toes your fingers your breath that's how you're training out these abnormal movements but in a sense it's not really training it out it's reinforcing the movements that you may have neglected because you just swung so far in One Direction either left or right let's assume you that you know you you proceed through that you you do the assessment you find some of these early warning signs you begin to work on the training what else can you do to to um again let's not necessarily even use the word prevent but delay the onset of this so in association with the REM sleep behavior disorder patients aren't getting a lot of REM sleep so I think sleep tracking is really huge in these patients so you know better than I do even that different sleep stages affect different functions in the body REM sleep is really important for not just memory formation but also dealing with your emotions that's how our bodies handle anxiety depression stress throughout the day these patients often have a lot of anxiety and a lot of depression and often aren't getting enough REM sleep so optimizing their sleep with Simple Sleep hygiene is huge now I mean one of the things I tend to worry about with sleep trackers is that they can create more anxiety and so my fear with that is you take that patient who's probably by now pretty nervous",
        "start": "00:35:37",
        "duration": 252.42099999999996,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "and you say we're going to start tracking your sleep and lo and behold oh your REM sleep is quite interrupted is that is that a is that a is that a good piece of information to have so I think it's a good piece of information I agree there is a person for a sleep tracker and there is a person that should not have a sleep tracker because they're just gonna enter a vicious cycle but knowing that they aren't getting enough REM sleep is really huge specifically for Parkinson's Disease so we know that the Melatonin signaling pathway in Parkinson's disease is off and they've actually done studies or they put people in front of bright light so lightbox therapy for Parkinson's disease early in the morning 20 to 30 minutes a day 10 000 Lux and that actually helps regulate the Melatonin signaling cycle and helps improve REM sleep in these patients so knowing that I think it could change outcomes yeah I'm going to be having Matt Walker back on the podcast in a few months and we're going to go into much much more detail about the pharmacology and the supplement side of how you can augment various sleep stages uh Matt's helped me a lot with this kind of stuff um so the other question I suppose I have you mentioned anxiety how do we know which one's the chicken which one's the egg here um you know by the time somebody is even told this information even if they're completely asymptomatic it seems to me that that would produce anxiety and so how do we know that the anxiety was pulling a causal role versus it's just the response to what's happening so from personal experience if you just talk to patients a lot of them will tell you I've never been an anxious person but in the last",
        "start": "00:37:43",
        "duration": 219.05999999999997,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "five years my anxiety is just through the roof and I think it has something to do with the dopamine signaling so if you think about is it a chicken or the egg thing in terms of sleep that's another question because yeah that's the sleep is promoting anxiety if you're not getting enough REM sleep you're not dealing with the anxiety so that's a whole cycle but and again we know that that again whether it be Dementia or Parkinson's disease these things disrupt sleep of course and disrupting sleep maybe makes them worse exactly exactly um but knowing that you may be at risk for one of these diseases I mean this is what we see every day whether it's a risk factor in terms of a genetic risk factor or a prodromal symptom in terms of REM sleep Behavior I think knowing the data doesn't tell you anything in terms of what's going to happen to you as an individual we haven't ever tried to do anything for people who have REM sleep behavior disorder just like previously we didn't try to do anything for people who had apoe Gene an apoe4 Gene we just kind of thought well you know they're at a higher risk for dementia and we're just going to let them you know be at that risk well this is our opportunity to do something about it because ultimately our treatment options once 50 of your dopaminergic cells are dead aren't so good we're just giving people back levodopa that isn't going to change the outcomes that this person ultimately is facing but maybe starting earlier knowing that this is a red flag maybe we are going to delay onset of full-blown symptoms or maybe we're going to slow the loss and maybe at that point the dopaminergic cells could be reversed we could repair the damage that's done or at least if we can't we can stop any more from happening and they may never get the disease well that last one is certainly",
        "start": "00:39:32",
        "duration": 255.4200000000001,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "interesting if we believe that we have a sense of what the environmental trigger is um of course it seems to me that well I don't actually know how the NIH is allocating resources to the biology of this disease I I can't so I can't comment as to whether it's adequately funded or inadequately funded but it would seem to me until we have a very clear sense of what's happening at the cellular level with the dopamine producing cells you know that's the thing we want to be able to Halt and so I mean I it's great to now shift our mindset from diagnosing breast cancer when it's metastatic to when it's you know a one centimeter early uh lesion but at least with breast cancer we know what to do when it's early you cut the damn thing out done and we knew that 200 years ago probably longer I mean certainly in the 17th century 18th century we knew removing and by the 19th century late 19th century we actually had perfected the sterile way to do this that's what we're still missing I think here is um so Step One is we now think we can figure this out 20 years before it's happening step two is removing the causative agent right there's no way to cut this out right we're not looking at a tumor that we can cut out but we also haven't ever studied doing anything this early which is a huge loss in my opinion because we know that there these people are at risk so we should be doing things and even if we're only moving the needle a small amount by certain lifestyle interventions or supplements which we know also play a role in disease works specifically B vitamins then you know we're moving the needle maybe just a little bit but maybe a little bit at the right time actually moves the needle a large amount yeah I mean again and I think you know",
        "start": "00:41:41",
        "duration": 243.299,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "we can think about that like how do we do that clinically with our patients it's one thing I think the challenge is how do you scale that up to being the um the standard of care where you know we without a biomarker it's very difficult to do that because prevention is too long a study you know it's actually the one thing that has made our progress for ascvd so great um there's really two things one is we have a really good biomarker in apob and ldlc the ldlc being not quite as good but but still decent right so we have this causative agent we have this thing that is necessary though not sufficient to cause the disease and when you have something like that you know almost without exception that lowering that thing will lower the incidence of disease and then it simply becomes a question of how long do you need to study it in your given population to see the reduction we don't have that biomarker here now we're going to talk about Alzheimer's in a minute we're going to talk about other potential biomarkers there and I'm very curious to understand from you the utility that we think of for example serum amyloid or Tau um but is there anything on the horizon with Parkinson's that we can even point to be it radiographically be it um certainly you know a blood biomarker would be the most desirable are there people working on this sort of thing so we didn't really talk about the difference in terms of histopathology for these diseases so Alzheimer's disease is what we call a taoopathy so you see a lot of amyloid and Tau proteins Parkinson's disease Lewy Body are called alphas and nucleinopathy so a different toxic protein builds up in",
        "start": "00:43:42",
        "duration": 221.241,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "these diseases and while we've Advanced a lot in terms of our ability to develop blood-based biomarkers for amyloid and Tau we haven't done so well in terms of alphas and nuclein so you can biopsy different parts of the body and get a good sense of alpha nuclein deposition so there is a school an alpha synuclein being this other protein deposition yeah and is it a misfolded protein yep exactly it's very similar to amyloid it's analogous to amyloid it develops into little Lewy bodies that go into your brain cells but also other parts of your body which is what I'll talk about in a second and cause degeneration of brain cells do we have the contrapositives so we know that there are lots of patients on autopsy that have amyloid and Tau who were cognitively normal um sounds like we don't have the opposite we don't have people with Alzheimer's disease that are missing amyloid and tau is that correct yes suggesting that amyloid and Tau if anything are necessary but clearly not sufficient what about on the other side with Alpha synuclein do we know that there are people who go who live a normal life with this present in old age and at the time of their death it's there as an incidental finding so it's a good question and I think there is a threshold before symptoms will present so when we're looking at like how much alphas and nuclein which will correlate to how many dopaminergic cells have been lost how like what is that number how much deposition do you need before clinical symptoms present so yes and in answer to your question there are studies that show well there is Alpha's nuclein deposits in this person's brain in this person's gut in this person's skin in this person's salivary glands but this person didn't have Parkinson's disease well what if that person lived five more years would they have",
        "start": "00:45:33",
        "duration": 252.27899999999994,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "Parkinson's disease I don't know maybe um so lots to unpack there is the alphason nuclein accumulation directly proportional to the death of dopaminergic cells yes pretty much so that means patients with Parkinson's presumably have more of it than Lewy Body um not necessarily because in Lewy Body you primarily have alphas and nuclein but you can also have amulet and Tau accumulation and in Parkinson's disease although it's still considered an alpha nucleinopathy you could have Tau deposition so I like to view these diseases as a Continuum I think the way that we have been trained to view these diseases is just wrong they are neurodegenerative processes and the underlying mechanisms are shared between all of them that's why we really have to start viewing them as such related diseases whether one person develops an alphason nuclein process or an amyloid Tau process is really less relevant in terms of what is the pathogenic mechanism that's driving that abnormal protein to actually be deposited and yes that starts with adequate it risk stratification risk assessment for a person because it's clear that this person may be on the path to developing an alpha synucleinopathy but what's driving that well it's still all a neuroinflammation autophagy problem so let's dial back and start more basically with what are the commonality commonalities between these diseases and can we target one and affect the outcomes of many so let's not talk about Alzheimer's disease then so this is the this is the kind of the elephant in the room um you know at least six million people uh in the United States have it that incidence also seems to be kind of rising disproportionate of the population you always run into the question are we",
        "start": "00:47:38",
        "duration": 236.8199999999999,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "just diagnosing it more are people getting sicker you know what's at the root of this [Music] um but let's not pick it up at sort of the uh the pathology so again this is not really a movement disorder therefore it's not really something where we see the office of nuclear accumulation everybody thinks of this through the lens of being an amyloid Tau problem uh maybe just let's explain people again what is amyloid what is Tau again let's explain what you know what's the app you know protein and how does it get cleaved and how does it turn into amyloid Etc yeah so toxic proteins what are we looking at so amyloid protein amyloid can be misfolded into things called amyloid plaques and if they're not cleaved properly they are sticky and they fold up into cells in the brain and can cause a whole slew of problems including neurodegeneration tau is something that will develop into an equivalent called a neurofibrillary tangle in cells Alpha nuclein on the other hand does the same thing it develops into Lewy bodies so basically these are physical structures these are actual proteins that due to misfolding um end up in and do they end up inside the neurons themselves do they end up adjacent to the neurons where do they actually accumulate it's inside the neurons inside the neurons and I assume that the critical problem is the relationship between that protein and the inflammatory state that comes with it or does the protein by itself interrupt the neuron minus the inflammation so that's a great question does the protein change cell signaling is that what you're asking correct by itself",
        "start": "00:49:37",
        "duration": 216.52000000000007,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "or is it the inflammatory process that's triggering I'll give you the analogy we know that cholesterol by itself when the APO B particle carries the lipid the sterol into the sub-endothelial space that's really not a big problem when it gets oxidized there and the inflammatory response comes to repair it paradoxically that inflammatory response is what leads to the tissue damage that results in atherosclerosis that results in the plaque formation and ultimately the plaque rupture so in that sense our bodies are doing the damage to ourselves I'm curious as to whether that's the case in neurodegenerative disease that's what I believe the case is whether or not there's some contribution that is directly related to impaired cell signaling once these proteins build up in the neurons that's possible but I think the bigger problem is what you just pointed out which is once these proteins develop the whole inflammatory Cascade that drives neurodegeneration is the big problem so it's essentially our body's reaction to these proteins being built up in the brain that are causing a problem okay now historically this was something that you only got to figure it on on autopsy person had dementia you clinically thought they dementia nobody was trying to distinguish between front and temporal you know occipital like those are all details this this person was normal they're no longer normal and maybe we'll do a dioxide a a an autopsy on Grandma and we'll figure out that this is what she had but a lot of that's changed recently so what's an amyloid pet scan and how does that shed light on this so let's even rewind it to just a regular pet scan yeah so an fdg pet scan which is really helpful when we're thinking about this whole frontotemporal parietal occipital pattern because if you get a",
        "start": "00:51:25",
        "duration": 267.96,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "fdg pet scan you're looking at glucose hypo metabolism in the brain well where is the brain hypometabolic maybe I'll even just tell people what what's going on so fdg pet you label glucose with a radioisotope and when you inject it into them the pet scanner is not an anatomic image like an MRI or a CT scan it's a functional image it's just looking for glucose uptake and so typically when you do a pet scan the brain really lights up the most because you're seeing so much glucose traffic to the brain relative to its size and so what you're saying is hypo metabolism hypomatabolism shows up as less signal in that area which says hey there's less metabolic activity less glucose went to this part of the brain versus this part of the brain versus this part of the brain correct and that less glucose correlates to neurodegeneration in that part of the brain or at least eventual neurodegeneration in that part of the brain so looking at patterns of hypo metabolism in the brain can be rather helpful in differentiating between things like Lewy Body Alzheimer's disease frontotemporal dementia because you see different patterns of glucose hypo metabolism so that can be helpful but it's not perfect it doesn't tell you what the underlying protein deposition is and if there's underlying protein deposition and you can see abnormal patterns quote abnormal as a part of normal aging so metabolism in the brain changes as we age and that's not necessarily A pathology it's could be just a process normal process of Aging but an amyloid pet so amyloid pets there are three different tracers that are available and FDA approved now essentially they all have the same sensitivity and specificity but what you're looking at with an amyloid pet is completely different than metabolism you're actually looking at a tracer that is tagging onto amyloid deposition in the brain and you're scoring what that",
        "start": "00:53:40",
        "duration": 236.70100000000002,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "Tracer looks like so how diffuse is that uptake in the brain and well here it's the opposite yeah you expect to see the area with pathology being the big signal as opposed to the lack of signal being the pathology with the glucose pet correct correct so amyloid pets can be helpful in terms of showing us is there amyloid deposition in the brain but there's a caveat there because we can see AMOLED deposition in the brain in cognitively normal people and in fact amyloid is abnormal but in many ways it's normal I read an interesting study and this is sort of unrelated but I can never get this fact out of my brain where they looked at young healthy people and young healthy 30 or 40 year olds and they made them sleep deprived so they said you couldn't go to sleep and then they did amyloid scans and CSF biomarkers for amyloid and found that after a single night of sleep deprivation amyloid deposition increased by five percent well that's because amyloid is present in everybody but we just started to clear it exactly so say in looking at an image at one point in time and saying that there's amyloid building up in the brain does that mean that that person is on the path to Alzheimer's disease if they're cognitively normal does that what does that mean is that reversible it doesn't really tell us very much more information yeah to me this is the thing that I'm most intrigued by is what what does it mean that there are people never mind just having amyloid pet positivity there are people who die and when you biopsy their brain you can't really distinguish their brain from somebody who had Alzheimer's disease from the amount of amyloid that's in there there's it's very difficult for a pathologist to look at this and tell you what this person looked like when they",
        "start": "00:55:38",
        "duration": 229.85899999999995,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "were alive and that's different from the heart right a pathologist can look at your heart on autopsy and can clearly distinguish who was healthy from who was not which is not to say a pathologist in a blinded fashion can tell you that this person had a heart attack because if they died quickly enough you might not see the damage but it's it's a stunning indictment of our ignorance of the brain and of the fact that the not this not to oversimplify the heart but the heart in some ways is an easier organ to understand it it behaves in a more mechanical way than the brain but um this makes it very difficult then to really stratify risk in an individual that's that to me is like this this is really less a philosophical this discussion for me and more of a practical one which is where do we need to act and how do we need to act and how do we measure progress yeah and like along the same lines there is looking at amyloid in terms of what does that tell you about cognition because the two could not be related at all so someone could have a ton of AMOLED deposition in their brain and be cognitively normal as you said but does that mean that they're in this weird delicate balance of if there is any more neurodegeneration or any more amyloid or any more towel which we'll talk about soon build up that they're gonna just fall off a cliff and symptoms will present or does that mean nothing in terms of cognition and this comes up a lot more recently with all of the new studies what are we looking at are we looking at amyloid deposition amyloid biomarkers are we looking at people's cognition what markers should we be following and I think you and I both agree that it really should be cognition yeah and I want to I made a note to actually come back to cognitive testing",
        "start": "00:57:33",
        "duration": 226.68000000000004,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "because I think it's super interesting um let's let's go on to Tau talk about these uh these neurofibular Tangles and and you know where do we see them being distinct from amyloid and then I want to come back and talk about amyloid serum amyloid as well and the the Advent of that in the past few years so right at the start of covid sometime in 2020 they FDA approved a Tau scan so there isn't a towel scan it again both amyloid and Tau Skins are not covered by insurance so the clinical utility of these scans is pretty low just because the cost of them is so high cost several thousands of dollars to get these scans to have to pay out of pocket but Tau Skins are and they're a ton of radiation so these aren't scans you just want to be doing willy-nilly like it's not like hey I'm going to go through McDonald's drive-through get a burger fries and then go head over and get a towel scan I mean that's I I I I want to say they're in the 10 to 20 millisieverts yeah yeah so that that's an insane amount of radiation for shits and giggles yeah it's you need a real reason to do that yeah exactly so understand there's a school of thought let's rewind a little bit here so there's a school of thought that says that and I don't necessarily subscribe to the school of thought but you first have amyloid then you have towel then you have neuroinflammation and then you have neurodegeneration so amyloid is thought to be one of the first markers but I don't I don't really agree with this 100 and I think every person is different so you can't really make this a hard and fast rule but looking at Tau scans in the setting of also having an amyloid scan could be helpful if you're just looking at Tau scans you're looking at does this person have towel accumulation in the brain these Tau scans may be more sensitive may may be more sensitive at detecting Alzheimer's specific Tau versus other Tau related to other Tau",
        "start": "00:59:26",
        "duration": 237.019,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "apathies like frontotemporal dementia but the utility of the Tau scan is that it tells us more about the progression or the likelihood that someone will develop cognitive impairment so it if someone has positive Tau on their Tau skin the likelihood that they'll ultimately develop cognitive decline is higher than just an amyloid so looking at them together although we would never do that because of radiation and cost concerns like you said if you had the amyloid and Tau simultaneously at the same time you could get a pretty decent snapshot of what someone's brain looked like and where they are now also this thing like amyloid where it's there all the time and we're clearing it and it's our potentially our impairment of clearing it that leads to the Pathology is so you're asking is Tau reversible actually I wasn't asking that but we should discuss that I guess what I'm saying is look we know that amyloid is present all the time but we again using sleep as an example sleep is a very uh powerful powerful tool to clear amyloid um is the same true of Tau I don't think we have a good answer for that we don't really know because we really haven't been looking at towel for that long yeah and so do we is there no serum biomarker on the horizon for town so there is um we can talk about serum biomarkers now because I think it's a good leeway so c2n if it's okay if we talk about the persivity test came out recently and that's actually a great marker for amyloid so it shows you the amyloid beta 40 to 42 ratio it gives so it encompasses someone's able e status so it gives an amyloid probability score based on someone's apoe status and the accuracy at predicting just from the simple blood test a positive amyloid scan is around 80 81 percent so super super high when you add Tau which now is not clinically available but is available for research",
        "start": "01:01:25",
        "duration": 269.081,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "purposes so tau217 is a new biomarker that has been brought to this game and looking at ratios of phosphorylated to non-fhosphorylated um p-tal 217 it adds to that so you're looking at accuracy of around 90 to amyloid skins as you know we've got one patient in particular who we're using this amyloid serum amyloid level to track interventions in and in particular one kind of unusual Intervention which is rapamycin uh so too soon to to really know with an N of one but very interesting that rapamycin is dropping his serum amyloid score well this patient is fascinating in so many ways if we want to think about just biomarkers because we collected every single biomarker possible minus the towel scan on him so first and foremost the old school way of diagnosing these diseases was to do a spinal tap and look at cerebral spinal fluid well we did that we looked at amyloid I was kicking and screaming not to but you and Richard overruled me yes I know and he was such a good sport was such a good sport such a good sport bless him um so we looked at CSF biomarkers in him and actually they were all normal all negative but we got the persivity c2n procivity test and that showed that it was positive that you know the likelihood of him having amyloid pathology was high we discussed this with so many people including our neuroradiologist colleague and she was like let's just do an AMOLED scan like let's get to the bottom of this we did an amyloid scan and he had amyloid deposition in the brain so this brings us to another really really interesting and exciting direction for these serum tests because we're noticing that they may be more sensitive at detecting early early Alzheimer's disease pathology even better than amyloid even better amyloid scans even better than CSF file markers",
        "start": "01:03:38",
        "duration": 259.02099999999996,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "and certainly more available I mean CS I mean it's it's I don't think people understand like yeah lumbar punctures are not the most invasive procedure in the world but if you have one patient that needs a blood patch you just never want to do that procedure again to somebody yep yep but looking at that and then having the ability to so readily repeat measures while we don't know if we can follow amyloid over time to see if our interventions are actually effective in theory it makes a lot of sense and as you pointed out we put them on a slew of neuroprotective agents and tried to optimize everything possible for him and including rapamycin and his amyloid biomarkers have gone down and now he's considered normal like low probability of having Alzheimer's disease but we know that his scan was positive it's a really fascinating case so let's let's segue then into something that I think is the the art form of this um which is the cognitive testing and it's in some ways the hardest part because it's not easy to standardize I mean there's a reason that we have someone like you in our practice because this is not something that me or Eve Suzanne Avi like the rest of us can't learn to do this um we can't Outsource it to a computer we can't tell our patients to go take a test that will give us the results There's real subtlety to this in terms of everything from movement to Vision to olfactory to these things so so give people a sense of what a cognitive test looks like what is the what is a gold plate cognitive test look like if you're really trying to probe the earliest Leading Edge of these types of diseases so we'll also correct you that some of it can actually be self-administered but some of it needs to be administered by a",
        "start": "01:05:49",
        "duration": 230.03900000000007,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "trained professional you can get a lot of information by having patients do some things by themselves but paying attention to them gives you a lot of Clues yeah I think that's what I meant I think it's like it's the uh well by all means you know clear correct me and point out what can be completely done automated but but yes I think part of it comes down to the the art I mean Richard has done a great job of sort of helping me understand what you learn by watching somebody take the test as well yes that that's the art of this assessment so first and foremost getting a sense of their olfaction is key because olfaction that's why I can't do this test today so I'm so congested yes I'm gonna go there's like nine things that we make them smell right yes yes there's nine things although we might be elaborating that battery to include a lot more so stay tuned for that great I'd fail that test measurement today so what what are those things that we make people smell and why does this matter so much yeah well I can't tell you what they are because then there are patients on the call that may know the answers very well okay so there are nine things that you're gonna have to smell yes and the idea here is you know cranial nerve number one is your olfactory nerve correct so you have basically from your nose a cranial nerve that goes straight to the front of your brain that presumably is like that Leading Edge of and immediate access to a cranial nerve that could be degenerating is that the thinking yeah and if you think you think out just sense of smell in general it feeds directly into the amygdala and the hippocampus so the whole memory circuit if you think about odor is actually one of the strongest sense that relates to memory if you smell something that you smell before you just get very nostalgic for whatever that experience is positive or negative yes it's very very ingrained into memory so it's one of the first",
        "start": "01:07:44",
        "duration": 246.08100000000007,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "nerves for lack of a better word first parts of the nervous system to degenerate in these diseases and it happens not just in Alzheimer's disease it happens in Lewy Body it happens in Parkinson's disease when it does happen in these cases we actually note that those patients are more likely to have cognitive decline so it really does relate to memory so yes first and foremost olfactory testings has covet changed that with people has made this so so difficult because the earlier strains of covid really did impact sense of smell and for some patients that sense of smell has taken months to a year or more to recover and for other patients you know it still hasn't really recovered and what are the implications of that long term I don't know if we know yet does it relate to later likelihood or higher likelihood later of developing a neurodegenerative disorder I don't know but it's something interesting and something that only time will tell okay so they get these little sticks these little cards and they have to go through that exercise okay what else do they what other types of things do we test for in cognitive testing so memory function is another one but there are so many domains to memory so there's registering the information reading registering auditory and visual registering of information which go into memory then the encoding process can you hear something do you remember it when you see something do you remember it does it matter how you report that you remember it is it is it reporting it by writing versus reporting it orally do those things matter as well so for most people auditory processing is more difficult and when you're doing auditory processing all of it has to be done auditor their auditory so I would ask you I'm going to read you a story and you're going to tell me everything you remember from that story and that's",
        "start": "01:09:47",
        "duration": 232.36,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "your immediate one learning of the information so I'll read it to you three times you'll try to remember as much as you can how much did you learn over those three trials that's all auditory and then in 20 or 30 minutes how much do you remember that's delayed memory so you're looking at immediate learning working memory and delayed memory now how do we ferret out the people who underperform these tests because of distraction yeah so that's why we do attention tasks so there are a whole slew of different attention tasks and speed of processing tasks usually you have to get people in a quiet room undistracted make sure their cell phones are off make sure they're not doing anything on their computers to really focus on the test but you have to add in these other cognitive exercises which are looking at their attentional capacity because often you will see distraction is a huge huge confounder when you're looking at memory if you're not paying attention to something you're never going to remember it yeah I I can think of imagine me trying to take this test at home like would be a disaster compared to if I you know woke up in a quiet place and got to take it under those conditions yep we tell people get a good night's sleep if you didn't get a good night's sleep we're not going to do the test for you because you're just not gonna do well on it make sure you do it first thing in the morning is really better or oh sometimes you feel relaxed don't try to squeeze it in between work meetings because you're gonna rush and again not really focus on the test so there are things that you should do to optimize your chances of giving this your best shot yeah to treat this like it's the one shot you get at the SAT exactly yeah your MCAT yeah um okay so that those sound really",
        "start": "01:11:43",
        "duration": 220.919,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "stressful what else visual spatial processing um and episodic memory which is really really difficult for a lot of patients actually it's one of the ones people struggle with so trying to see where an object is and remember the sequence that you saw that object so you're given a series of objects when did you see this and what order put them in the order that you so like a series of cards for example yes so you got to remember if you saw the car before you saw the garbage can [Music] difficult and and you know only shown four or five or six objects but when you're shown 10 or 12 objects it becomes very very challenging so that's really testing your working memory but also some visual spatial um visual spatial skills are tested a lot by writing and drawing copying cubes drawing clocks old-fashioned things from med school that you probably remember actually give a lot of information and there's still things we use today what about [Music] um horsepower like executive function problem solving yeah IQ test stuff IQ test stuff so verbal learning and um being able to pronounce very tricky words is actually a really good proxy for IQ and is one of the ways that we look at that um just showing us an understanding of what this person's cognitive Reserve is because having that Foundation is really important for understanding what how you should interpret the results to follow because if someone's IQ is much lower than you expected then you really have to interpret the rest of the results in the setting of that",
        "start": "01:13:34",
        "duration": 210.70100000000002,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "so there's obviously a language bias then so how are you testing like if you're encountering a patient for whom English is their second language um how are you able to administer this test and not be misled by it yeah so there are different versions of the test and if English is not your first language it's just something that we note because we could get access to all different versions of the test but it is challenging to do that because the Norms are all different and you have to just purchase a bunch of different forms and norms ideally you would do this in person but I know since covid it became more possible to do this remotely is that is that still do you still feel that's the case yes there are certain pen pen and paper tasks that we send to patients because you do need to do some of the motor activities by writing but pretty much we can do everything remotely now how long does a test take oh an hour an hour and a half okay that's less than I thought I thought it was longer yeah other things that we test for so executive function is really really Broad and really cross-cutting on a bunch of different tasks but without giving away too many Secrets thinking about naming certain categories of objects or naming certain um words that start with specific letters that's how you look at executive function now how do you retest people what's the Frequency at which you can retest so that you don't sort of run the risk that they're learning the test and improving because of you know getting better at the skill of the test as opposed to getting cognitively better so you change the forms first and foremost so you don't really administer the same test multiple times interestingly apoe4s are immune to the learning effect so they actually don't learn as well so you can retest them in",
        "start": "01:15:21",
        "duration": 226.26000000000005,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "about six months and learning isn't really a factor to consider for them um but there are equations to correct for that when you're looking at normative values well how often does the FDA use the performance on a battery of tests like this as an endpoint oh I mean when the FDA is using things they're looking at things like mini mental status and the Montreal mocha test tell folks what these two yeah yeah so one is the Trump test so if people have heard of that how Trump based a very difficult cognitive test well yes that was one of these where you have to name this is a lion this these are a sequence of numbers just repeat them back to me forward and backwards so they're basic 30 question tests where you're asked what the date is where are you who's the president who's the president they're very basic and rudimentary these are tests we would use in the emergency room when we wanted to know if someone was psychotic or heavily under the influence of alcohol drugs things like that yeah and to be fair they do give you a very good sense of if someone is very cognitively impaired they're going to do very poorly on this test but for most people who come to you and say I you know I just notice I'm forgetting things they're probably still going to ace the test and it's not giving you a good sense of well is it an actual memory problem or are they distracted like we pointed out before is it an attention problem like there are so many things that can go wrong when someone says that they're forgetting that you really have to dissect that problem more the potential risk here is that we're not using a sharp enough outcome tool to measure either drug efficacy or timing and that kind of gets to another question which is are we looking at intervening too late so I think most people are familiar with",
        "start": "01:17:13",
        "duration": 241.019,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "the notion that the um the track record for Alzheimer's treatment drugs is pretty abysmal uh how many FDA approved drugs are there for treatment of Alzheimer's disease well if you count if we have danapazole or Aricept we have so there's a couple in the same class I think there's three of them and Namenda those are the big ones and ajikanumab I mean that's all we're looking at in educated about being the most recent one approved about a year and a half ago which now has had a lot of backlash and Medicare is not paying for it so it's been a whole big mess yeah which is and we've I think we've discussed this on a previous podcast um so I won't I won't rehash it but the the gist of it is basically this was a drug that was targeting amyloid directly it really split the FDA and I I think members of The Advisory panel even resigned over its approval um if you're in the bowl camp on that you'd say that that drug is misunderstood that drug would have efficacy if used early enough and if you use the right metrics to assess its performance if you're in the Bear Camp you'd say it's an incremental drug that if it has any benefit doesn't come close to justifying its cost yeah and I think this gets back to back I don't know the answer to that question but this gets back to we need to do a better job at identifying what stage someone is in the disease process and where when and how the disease can be reversed if it can be which I think that it it can again I think the breast cancer example is really apt here which is my fear with all of these neurodegenerative diseases is we are acting at the wrong time exactly and it's exactly like saying we take a bunch of women with stage four",
        "start": "01:19:14",
        "duration": 223.74100000000004,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "breast cancer and we do lumpectomies on them and they don't live any longer and we think therefore the lumpectomy has no place in the treatment of breast cancer when in reality the lumpectomy has no treatment in the place of women with metastatic breast cancer and it is the standard of care in women with stage one breast cancer and it will save their life exactly and that's my fear is when it comes to neurodegeneration we don't know what this as you said we don't know the stages we don't know the difference between stage one stage two stage three stage four and we certainly don't know what treatments to apply when and most of the treatments that are being applied are being applied at what would be the equivalent of stage four exactly so by that time what can you really do because you can't reverse the neurodegeneration once it's already happened you have to start earlier and another large Target for these drugs and new biotech companies are the inflammation process the neuroinflammation which is a huge factor and I do think plays a huge role but again the question is in who and when and without having plethora of biomarkers that you're looking at to really hand pick patients appropriately I don't know how we'll show effect efficacy of these drugs let's go back to something you you alluded to very briefly earlier which is the role of the visual and auditory systems in these diseases so I think it's generally well accepted that there's an association between hearing loss and dementia is it Alzheimer's specific or all forms of dementia um it's all forms of dementia but most of the literature is surrounding dementia as a broad term which they usually mean Alzheimer's disease I've talked about this with Richard quite a bit and and he he's really of",
        "start": "01:21:06",
        "duration": 216.24000000000004,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "the mindset that there's a causative relationship there and that's a big deal because again if you can just say well there's an association between hearing loss and dementia it's like well okay yeah I mean that makes sense but if you think that that relation is causative and that's why it's just so important to understand causality it means that treating hearing loss will reduce the risk of dementia it means that the it means that screening for hearing loss early and treating it aggressively will improve outcomes and that's totally different from just saying yep you know they're just highly Associated um so Richard's view is that yeah we should be doing this I think you share that view yeah we should be doing this so there are a lot of schools of thought on how this is related to neurodegenerative diseases and Alzheimer's specifically but the one that I think I like the most are the two that I think I like the most are when you can't hear your increasing cognitive load to the brain which is taking cognitive function or taking cognitive abilities away from other processes of the brain so for example memory function working memory because your brain is focused on trying to hear or trying to see it's using all of its power to do that and it's diverting resources away from building memory function but the other factor which I think really relates to the movement aspect is our brains need sensory input and when you aren't giving that sensory input to the brain you lose that function and hearing is so important for verbal processing vision is so important for visual spatial processing these are all cognitive functions that if you're not giving the sensory input that the brain is craving you're probably not building those Pathways anymore you're not diversifying",
        "start": "01:22:54",
        "duration": 229.97999999999996,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "your brain your brain's experience I think both of those are they again I don't know if those things are right but if if if there is a causative relationship between Visual and hearing loss those two mechanisms make a lot of sense I want to make sure I understood them the first is if you were becoming deficient in those areas you're wasting quote unquote more of your cognitive energy on the acquisition of those inputs to the system and in doing so you're detracting from the capacity to do other things we have a finite amount of this reserve the second thing is you're now deficient at Gathering inputs that Foster the neurodevelopment plasticity formation creation of better outputs so you're going to process information worse if you can't hear you're going to process your environment worse if you can't see correct correct so you'll move worse you'll think less and there's just clinical evidence to support this so there's something called recredescence in stroke when someone had a stroke a while ago it might have been a small stroke it might have been a large stroke but they pretty much recovered from their stroke until their body's under some sort of other stress so they have a urinary tract infection or a pneumonia something that puts any sort of stress that stroke those symptoms that once were a part of their Ultra come back out called recruit Essence it's like the brain can't handle doing too many things at once it can only divert it can only deal with that wound in its brain by having all of its brain power focused on it if if it doesn't then it's diverting some its resources someplace else then those symptoms come back out again it's sort of similar to that wow um let's talk about oral health this is something you're interested in something you've spent a lot of time thinking about it certainly makes sense",
        "start": "01:24:49",
        "duration": 235.2790000000001,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "um I I've as you know become more and more interested in this idea that the health of your gums the health of your teeth is actually quite a strong predictor of the health of you as an organism um it's hard to have very poor health in your mouth and have very good health in the rest of your body how do you think this pertains to the brain specifically 100 I could not have said that better so there are certain red complex pathogens three bad guys in particular one treponema denticola p gingivalis and tea for Cynthia these microbes are associated with a higher risk of amyloid deposition Tau deposition and inflammation so knowing if you have these red complex bacteria which Drive periodontal disease I'm sorry these are all gram negatives gram-negative bacteria right so when you have a high colonization in your mouth with these bacteria your peripheral inflammation is driven way up and when you think about somebody who has an apoe4 for example a three four or four four why would you ever want them to be under any more inflammation if you know E4 is priming microglia activation then adding any layer of something that's going to trigger more inflammation is just a bad idea so focusing on oral health especially in high-risk patients is huge and I think really an overlooked part of this whole picture there is some debate and there is some evidence for this that potentially these bacteria can ectopically migrate either through the blood or through cranial nerves to the actual brain because they've identified them in autopsy specimen but I don't know if that's true I don't know if it's the bacteria going to the brain themselves it's causing damage I think it's more of the inflammation that's triggering part of the damage and it being in such close proximity to the brain having all of these cranial nerves",
        "start": "01:26:49",
        "duration": 253.91999999999996,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "kind of right there right by the mouth I think that's the bigger issue and do we know if the greatest driver of that risk is simply poor oral hygiene poor oral hygiene but also you know which which comes first here so dental implants root canals just external hardware in your mouth those are just they're just nidus for these bacteria to form on and we notoriously don't clean them as well people who wear retainers at night after their braces or a mouth guard because they grind their teeth at night they aren't really cleaning these a specimen very effectively and they're just loaded with bacteria and often flossing's overlooked and it's not just flossing flossing is great but really using a water pick or an interproximal brush or something that goes in between the teeth that has a little feather at the end that you're really scraping away the bacteria is what you need okay let's return to ad and double click on the genes again I think most people listening to this if they've spent any time listening to this podcast they're very well familiar with the apoe4 situation uh we've got these three isoforms for the same gene8 but we've got the two three and four isoform and they can combine in every possible way so there's six combinations the normal one is the three three combo that's 50 to 55 60 of the population correct yep the high risk Gene is the four high-risk isoform is the four the low risk isoform is the two the two seems very rare I don't think I've ever seen a 2-2 maybe I've seen one person with a tutu I've never seen a tutu but two threes two fours and it's five percent less than five percent of the population but let's talk about the four fours and the three fours um these are your higher risk populations your three fours are",
        "start": "01:28:56",
        "duration": 223.42000000000002,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "probably 20 to 25 of the population four fours or one to two percent of the population um in our practice it's four or five percent of our practice is four four but I think we have a selection a little bit of a selection bias maybe maybe more than that actually uh obviously when you were still at Cornell you saw lots of four fours that was probably a quarter of your population yep you've often said and Richard said this as well you don't get that stressed out when you see a patient when you have a really clear sense that their risk is predicated through their e4ness yeah uh and I mean not to make light of E4 but you kind of talk about it like it's it's the enemy you know easy peasy piece of cake yeah um so first expand on why you you would make such a statement and then two I want to talk about the things that are able to either make the E4 worse or potentially even make the E4 better meaning reduce the risk or uh amplify the risk of E4 we know what to do when we see an apoe4 it's when somebody doesn't have an apoe4 and has a family history that's very notable for dimensional Alzheimer's some neurodegenerative disease also Lewy Body which Louis e4s are at risk for Lewy Body dementia 2 which is something that we frequently Overlook um so when we see a 3-3 and we see a family history then we start scratching our heads like well like what is the pathogenic mechanism that's driving this this person in this family to develop Alzheimer's or a related neurodegenerative disease when we see an apoe4 we kind of understand more about how that impacts the body we understand its role",
        "start": "01:30:49",
        "duration": 224.85999999999996,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "in peripheral cholesterol which also relates to its role in central or brain cholesterol we know how it impacts their ability to metabolize carbohydrates we understand kind of what we're up against when we see it and I just want to emphasize because so many people come and they're so afraid once they found out that they have an apoe4 or you know they're just so afraid because they have a family history and they don't want to know what their genes are but your genes are not your destiny there are ways that we can intervene to mitigate some of the detrimental effects of these genes so what are some of the other genes that are cousins of E4 that travel with E4 or that frankly don't but add independently to risk or subtract independently from risk yeah so apoc1 and Tom 40 are two genes that are located right around the apoe4 Upstream yeah two M's in Tom right yeah Tom with two M's 40. um and they are tightly associated with apoe4 meaning they're linked most people in if they inherited the quote harmful copy of apoe4 I'm gonna say quote because I don't know how harmful it is anymore now that we're better at managing it but they'll also inherit the quote harmful copy of Tom 40 harmful copy of apoc one most cases 90 of the time but in some patients they don't and are these protein coding genes or are they in the non-coding regions that Tom 40 and C1 there are protein coding chains so when you don't inherit them and you're looking at someone who is a three four or a two four two fours are really great examples because if you see that they inherited the lower risk variance in Tom 40 or apoc one then I'm thinking well they're less likely to behave like an E4 and more likely to be it's more like a two three like a two three versus the other way around then I get very worried about their E4 expressing themselves and I start thinking we need to really",
        "start": "01:32:42",
        "duration": 266.04,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "hammer down on their cholesterol we need to do much better with vascular risk factor control yeah so the Tom 40 apoc one can swing the balance yes yes so it does provide a huge piece of information for a small portion of people but for that small portion it's really really life-changing and changes management yeah so what about um genes that are less tightly linked to apoe4 that either up or down uh turn the risk so clotho is a big one and I know you're a huge that's my favorite Jean yeah you love cloth I love you some cloth though um so clotho seems to offer a protective role against apoe4 it doesn't completely erase the harmful effects of apoe4 but it really does lessen it and it has an effect on the rate of cognitive decline so if you have clothoheterozygosity then we're more optimistic about how we look about what we're talking about we say heterozygous meaning you have one wild type and then you have one of the protective one which is the klvs snip yes um and this is we talked about this the other day in the literature this is like I don't know one in six people would be heterozygous it's actually pretty hard to make this diagnosis because there is no off-the-shelf test for this snip no there's not you need whole genome sequencing yeah which again for the listener that is a real impediment to this work right now it is you know we have some e4s in our practice E4 e4s who you and Richard have looked at and like you don't you don't even think they're worth talking to they're so uninteresting which is a good thing like if if you don't want to talk to them that's a good sign um E4 e4s think about that yeah and I remember the first time Richard met some",
        "start": "01:34:56",
        "duration": 231.89999999999995,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "of these people to you three years ago he's like I'm not this person's this person has nothing wrong with them and will have nothing wrong with them and I'm convinced that they are you know cloth okay lvs's but it you know it's not just that you got to spend all the money on the whole genome sequence it's that you got to get somebody to go through the data and pull out those uh pep you know pull out the sequence yeah Richard and I are working on a process of streamlining this it is so labor intensive it's a little back of the napkin mom and pop right now but you have to manually go through the genome and pull out all of the relevant Snips there's no Snips meaning um portions of the DNA that pertain to risk um there's no fast way of doing it and more than that you have to do it in a logical way because if someone has an E4 versus an E3 you're going to look at a completely different set of genes and a completely different set of snips or variants then you are going to look at first it was so frustrating that three like this is such an easy problem for AI to solve yes and it doesn't need that many resources it just needs somebody to say you know what we should just automate this once and for all spend a few million dollars on the process yes and everybody can drop their whole genome sequence in there and you can get the answer that's what we're trying to do a better job and work on because I think we can develop a software that is able to do this more rapidly but right now it is so labor intensive and so expensive yeah I also think that the klvs cloth mutation would be a great crisper Target one day yes yeah um I I I think the the longevity benefits of that of that transformation would be enormous but going back to I mean just teaching a software how to do",
        "start": "01:36:52",
        "duration": 231.78,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "this part of it is and thinking about the example that you pointed out that there's you know and there's e44s that we're just not interested in part of that is you have to understand that person's risk factor so if they have no family history of Alzheimer's disease or a neurodegenerative disease whatsoever their lower likelihood of getting this a disease later even if they're four four yeah okay the other one I know we've talked a lot about is mitochondrial haplotype this is a bit more complicated because it's not a gene per se so explain what the mitochondrial haplotype is and what it tells us about risk and how difficult is that to measure so cytochondria going way back to Evolution so they were once thought to be their own organisms that the body sort of devoured and developed a symbiotic relationship with so they are one of the few organelles in the cell that have the only organelle in the cell that has their own genome so the mitochondrial genome has genes that relate to oxidative phosphorylation or how the body makes energy so the Cox genes and NAD genes all of these genes are encoded in the mitochondrial DNA mitochondrial haplogroups are labeled based on what different variants are found in different genes in that mitochondrial DNA and there are more than 4 000 mitochondrial haplotypes so there are a ton of mitochondrial haplotypes and again they're based on what variants are common among all members of a shared group so for example there is a risk snip that I wouldn't say risk there's a snip that is associated with mitochondrial haplogroup H and all members that are categorized as hapel Group H have this variant so two things one how difficult or easy is it to determine your mitochondrial haplotype is it as complicated as is it",
        "start": "01:38:48",
        "duration": 262.85900000000004,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "more clotho or more Tom 40 E4 so it's very very difficult 23andMe generates their own mitochondrial hapla groups and the way that they do it is they have a few markers that they pull out of the DNA that pertain to each specific haplal group so that's how they are identify someone's haple group it's actually not perfect if you really wanted to know someone's Apple group you have to sequence the entire mitochondrial genome and use specific software no I don't think 23andMe can do that right no I see not 23 and me cannot but you can do it through whole genome sequencing adding on mitochondrial DNA sequencing and analyze the mitochondrial genome but you need specific software to do so and it's really much more challenging than the whole genome or the so why does this matter why do we want to know the haplotype or haplan group of the mitochond chondria how does it tell us less I mean let's just assume it tells us risk is up one uh but if even if it's telling you risk is higher what Insight does it impart as far as preventative strategies so super helpful and understanding risk especially for apoe4s but also for other neurodegenerative diseases and interestingly the same haplotypes that put you at risk for Alzheimer's also put you at risk for Parkinson's Disease so for example haplotype h if you have this haplotype and you're an apoe4 it seems to enable the E4 or act synergistically with the E4 so when we see that combination we become a little bit more concerned about this person versus somebody who is a haplogroup K because K seems protective especially for eight Bowie fours okay if you have someone that's in a type h do you have any sense of what preventative measures are more important than others so just knowing what type of haplogroup they are gives us insight into how their mitochondria are behaving",
        "start": "01:40:59",
        "duration": 238.14100000000005,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "so if we know someone isn't an efficient energy producer or their mitochondria aren't acting efficiently let's rev up their zone two let's try to get them as many mitochondria as we can let's increase their density of mitochondria because that might circumvent some of the negative effects of their mitochondria just not working as efficiently at generating ATP or energy so talking about that talking about exercise my view has largely been that there's probably no activity that you can participate in that will have a greater impact on your brain's Health than exercise now obviously you have to take that with a caveat all the exercises in the world won't help you if you're sleeping four hours a night it can't offset that much damage but in terms of additive activity it seems to me exercise matters more than anything else it certainly matters more than the the finicky Nuance that someone might make in their diet of like oh I'm going to take out nightshades and you know all of a sudden that's going to fix all my problems or something sort of idiotic like that um would you agree that exercise has the most potential to improve brain health and that's not just in the healthy but obviously in the preventative strategy wholeheartedly I think exercise has the potential to move the needle the most so what is it about that um what are the because exercise does so many things which what do you think are the levers that it's pulling so when I think about exercise I kind of break it down into categories in my head so there's the coordination proprioceptive balance type exercise which you can include dance under that for example which some people don't really think about dance as an exercise but it's an incredibly powerful exercise for the brain because you're not just getting the physical heart rate",
        "start": "01:42:58",
        "duration": 232.52,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "elevation you're getting the cognitive training which in is involved in the coordination and the choreographed movement so you're trying to process the visual information and make your body do that activity or do that movement which is both a cognitive workout and a physical workout so this is a way of increasing cognitive Reserve increasing neuroplasticity that has probably a different effect than something like Zone 2 for example which is involved in improving someone's energy metabolism and inefficiency which is very different than strength training which is equally important for building muscle mass and metabolic health and so on so you have the metabolic component right you have the vascular component you then have like bdnf um what role do you think bdnf plays here so I think bdnf plays a huge role but it's hard to say how much that plays versus how much just higher intensity cardio exercises increasing cerebral blood flow which is increasing nutrient oxygen delivery to the brain but bdnf is what we call a fertilizer for the brain so it helps protect new brain cells but also helps grow new brain cells specifically in the temporal lobes or the memory centers of the brain so stimulating bdnf is a potential one of the potentially large benefits of exercise specifically does anything stimulate more bdnf than exercise I don't think so okay um what role does hypertension play here you know in the we there are certain organs that are so clearly related to high blood pressure negatively right so the kidney and the heart there's just no ambiguity more blood pressure is just bad for the kidney is bad for the heart once once Baseline perfusion levels are met obviously every organ suffers if blood pressure is too low in a pathologic sense of somebody's hypovolemic in shock",
        "start": "01:44:56",
        "duration": 247.619,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "or something like that but you know 120 over 80 is all you need to perfuse the kidney and to perfuse the heart and we now know that 135 over 85 that's going to start causing damage what do we know about that with respect to the brain so the Sprint mind study looked at this and lower is better so 120 over 70 more strict blood pressure control seems better for cognitive outcomes long term I will also Circle back and say that what we see in some of these diseases especially the Lewy bodies and Parkinson's is autonomic instability so blood pressure fluctuations which is very tricky to deal with because what we'll see is at night someone may have higher blood pressure when they're laying flat but when they're up and about during the day when you're actually measuring their blood pressure it's not very high so you could be misled living a Fool's Paradise thinking that they're actually you know Norm attensive which we'll consider less than 120 over 70. our brain but they're not so you really gotta check what their blood pressure is at night when they're laying down or first thing in the morning before they get out of bed yeah it's funny so this I'm just going to get back up on my soapbox climb back on it so I was on my soapbox a minute ago pleading for somebody to do the AI work to figure out so we can figure out everybody's clotho status and mitochondrial haplotype like that this is this might even be a slightly higher soapbox people know how much I'm a fan of continuous glucose monitors because that type of information whether you only choose to wear one of these things for a month or you choose to wear one for a year even if you're not diabetic the insights are profound and they will forever change the way you think about eating exercise stress and sleep 100 they just they show you that it will play as much as I'm a fan of that",
        "start": "01:47:00",
        "duration": 226.26100000000002,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "I would right now get rid of CGM for the non-diabetic if I were Czar for a day if in exchange I could have a continuous blood pressure monitor that was perfect and seamless and you could stick a patch on and have real-time continuous blood pressure monitoring that would be even more valuable for the reason you just stated 100 we I I and this is one where I just lose sleep over it for myself and for my patients which is I really don't know what my blood pressure is most of the time even if I check my blood pressure twice a day sitting at my desk like it tells me nothing about what my blood pressure is the other 23 hours 59 minutes and 30 seconds of the day and that we don't have a tool to do that yet well and I've tried every supposed continuous blood pressure monitor out there the ones that work are so cumbersome that you can't use them like the ones that the clinical grade stuff where it's a cuff attached to a big battery pack and you're walking around it looks like you've got an lvad I mean those work but they're not practical no and then the little wrist bracelets and stuff are total garbage so we're just sort of waiting for some technology to to change the game and I just can't wait for this and I hope it occurs soon because it's it's such an urgent need I not just in terms of everything we're talking about but when you start to think about cardiovascular disease we're really missing it's like imagining imagine not knowing if you were a smoker like it's as dumb as that sounds like you don't you can't tell if you smoke or not but you you might like yeah yeah no we have no data and what's worse is it's very difficult to think of how you could develop a vice a device that isn't interfering with your sleep because if you want to check it when you're sleeping you don't want it to cause",
        "start": "01:48:52",
        "duration": 226.62000000000006,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "another problem cause you not to sleep but then you start thinking about well even if you did have just high blood pressure at night what can you do well there probably are things you could do because they're short acting medications that you could maybe just dose before bedtime and you know during the day when your blood pressure is fine you're up and around great but at night when you're actually hypertensive which is you know half of your day essentially you are treating that but right now we're just living in Fool's Paradise because we have no idea what your blood pressure is doing at night okay so good to know that or bad to note but good to note that we we got to keep our blood pressure low here as well yeah um we all know that Alzheimer's disease disproportionately affects women two to one my belief personally which is not unique is that I think it's the hormone reduction that's doing that I don't think it's I think very little of that is explained by women slightly outliving men I really think it's the sudden loss of estrogen in particular and maybe testosterone that that feeds into that um what do you do you think what do you think is the is driving this two to one gap between men and women in Alzheimer's well so something that's interesting and recently discovered in nature I think it was published in April or maybe may but we can link to it in the show notes the MGMT Gene so the MGMT Gene is a very powerful DNA repair Gene in both men and women but it seems to there are certain variants in this Gene which seem to Independent of apoe influence Alzheimer's risk specifically in women and this Gene is related to breast cancer as well so what is it about women that put them in a different category even in terms of what genes matter than men it's more than just hormones I think",
        "start": "01:50:47",
        "duration": 219.96,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "but I I don't know the answer I do think hormones play a huge role as you pointed out and the menopause cause transition which is a huge area of research right now and something that we really focus on in our patients is something that you know has to be a high priority in women specifically because of this role of hormones but I think there are other factors at play um and just thinking of the counter argument to that when you think about Lewy Body Parkinson's well that's much more common in men to a two to one prevalence in men versus women and is it sex and hormones that are driving that probably but in what way I don't know yeah well that's that's actually what I was going to ask you is what do we think is explaining the opposite which is why are men getting Lewy Body and Parkinson's two to one more than women I I I don't know I don't know what it is about the male sex that's really giving us a higher risk or a lower risk for a disease but you know every it's easy to point to hormones as the answer but I don't know if we have the data out there to actually say that I think one day we'll be better at really pinning down someone's risk in terms of incorporating biological sex and genetic risk to give someone a more accurate understanding of what their individual risk is and then be able to give them lifestyle and preventive strategies based on what we find there but I don't think we're there yet it's hard to know what to do with hormones especially in men so kind of thinking about this in terms of a wrap up right it seems that there are two big themes that that have come up here one is the higher your cognitive process the higher your cognitive Reserve the more likely you are able to weather a storm here so similarly",
        "start": "01:52:36",
        "duration": 233.47999999999996,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "in a recession it's easier to weather a recession if you're not living paycheck to paycheck [Music] um it sounds like if I've understood you the same is true on the movement disorders that maybe the more facile you are with movement the more Reserve you have to combat And Delay the progression and or onset of the alpha synuclein based pathologies as well yeah I think which might by the way be the kind of the other reason why a diversified portfolio of exercise matters yeah I think when you think of brain health it's not just the cognitive piece but it's the movement piece too because there are nerves throughout our whole body not just our brain so when we think about how do we optimize our brain health it has to be yes diversifying your cognitive experiences and managing your vascular risk factors but also bringing in the movement piece is such a huge piece of the puzzle and something that I don't think people have really come to realize because we've been so hyper focused on looking at what what's the blood work show like let's look at what the movement patterns show too yeah this is something we're really excited about you and Beth working on together with our patients and then hopefully we can sort of figure out a way to share this more broadly which is you know using adding movement to cognitive testing to identify these problems as soon as possible again on the movement side you know we've been doing this for a long time and you know you can sort of say I know you're not in pain now but because you move that way you're going to suffer an injury at some point it might be a year from now might be 10 years from now but you're on you're on the wrong path if if we make these changes now you're on a better path when we can start to make",
        "start": "01:54:36",
        "duration": 226.31899999999993,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "that same relationship between movement and movement disorders I mean that's fantastic that's taking it to the next level and that's where we need to be and for all the people that are listening who may be at risk for one of these movement disorders or have a loved one that is suffering from it getting to the Crux of the movement problem might be the key to answering the question of how to prevent the disease so I don't want you to overstate it but my final question for you kellyanne is with ambition but not wishful thinking where do you think we can be in five years with respect to everything we've talked about today so I will say that no one has incorporated exercise and movement the way that we're looking at it now I think just that alone is going to push the needle so far in the direction of making it advance in the world of movement itself in the world of Alzheimer's like I said they're so related whatever we learn about one disease tells us so much about the other disease we have to stop thinking about them as so separate and more think about them as a Continuum I don't know what the future holds but I think if we start changing the way we're viewing the diseases and put them more broadly under the term of neurodegeneration identify what the problem is from the get-go not look at Amwood not look at Town not look at Alpha Cent nuclein as the ultimate problem but scaling way way back I think we can get much further than we've been and you think we would be able to do that with a better attention a finer tooth comb on cognitive testing which includes all of the dimensions you've talked about plus movement assessments you think that those together even before biomarkers can start to give us you know that that very early indication of where someone might lie on a spectrum",
        "start": "01:56:30",
        "duration": 245.20299999999995,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "and genetics I don't think you can do this without understanding genetics and family history I think with those pieces of information yeah we can move the needle pretty far and you're confident that we can then Target preventative strategies yeah once you understand what someone's at risk for and understand what their Baseline is you can curate what strategies there are to prevent it in a particular person yeah we were talking about this last night um I just don't think there's any set of diseases that are more frightening than this I think when you look at all the big buckets on the on the death bars that we that we so fastidiously keep track of total heart disease is the number one killer cancer is the number two killer I think we accept those risks I think we kind of get it you know and and deep down I think we all kind of hope we're going to die of a heart attack in our sleep and when we're 96 and you know and that's that and and um then nobody wants to to die that way and nobody wants to die period I suppose and certainly nobody wants to get cancer but but there really isn't any of these neurodegenerative conditions that doesn't just leave you feeling completely petrified yourself and then completely uh at a loss for what to do to help somebody who's suffering from it yeah so I I applaud you for being able to go into the world's one of the three most depressing fields of medicine and then somehow carve out an optimistic piece of it honestly our waiting list at Cornell was more than five years long and what one patient actually said I was told by my doctor that it's harder to get into this Clinic than it is to get into college which is really really sad but that just goes to show the",
        "start": "01:58:35",
        "duration": 223.04,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    },
    {
        "text": "tremendous need for people to start re-evaluating how and when we're looking at disease so so much need and the first thing that patients would say when they would come to see us is how petrified they were they saw their family member go through such a disease that robbed them of essentially the person that they were they're no longer able to communicate they don't recognize them like that's a terrible thing in so many ways so much more terrible than a heart attack at least you still have your cognition I mean granted none of these things are good but just losing your whole person is just so so hard and that experience for so many people really drives and empowers them to do everything that they can to ward off the disease and most people would leave in tears just because they feel like for once someone is listening and there's something that they can do to anything that they can do to just change their fate and their fate may not be what their parents fate was or their grandparents fate was it's huge well kellyanne thanks for sitting down with us and walking through all this stuff it's super interesting and I'm I'm excited about what we uh what we can what we can do together yes me too thanks for having me I'm looking forward to more discussions in the future [Music]",
        "start": "02:00:26",
        "duration": 199.19999999999996,
        "title": "#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D."
    }
]